Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

Alessio Amatu; Ludovic Barault; Cátia Moutinho; Andrea Cassingena; Katia Bencardino; Silvia Ghezzi; Laura Palmeri; Erica Bonazzina; Federica Tosi; Riccardo Ricotta; Tiziana Cipani; Patrizia Crivori; Rosalinda Gatto; Giuseppe Chirico; Giovanna Marrapese; Mauro Truini; Alberto Bardelli; Manel Esteller; Federica Di Nicolantonio; Andrea Sartore‐Bianchi; Salvatore Siena

doi:10.1093/annonc/mdw071

Article2015

Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.

Alessio Amatu, Katia Bencardino, Ludovic Barault, Andrea Cassingena, Erica Bonazzina, Silvia Ghezzi, Cátia Moutinho, Federica Tosi, Riccardo Ricotta, Elena Magni, Rosalinda Gatto, Giovanna Marrapese, Manel Esteller, Alberto Bardelli, Federica Di Nicolantonio, Andrea Sartore‐Bianchi, Salvatore Siena

Article2013

Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu, Andrea Sartore‐Bianchi, Cátia Moutinho, Alessandro Belotti, Katia Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna Esposito, Michele Nichelatti, Manel Esteller, Salvatore Siena

Preprint2023

Data from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu, Andrea Sartore‐Bianchi, Cátia Moutinho, Alessandro Belotti, Katia Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna Esposito, Michele Nichelatti, Manel Esteller, Salvatore Siena

Preprint2023

Data from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu, Andrea Sartore‐Bianchi, Cátia Moutinho, Alessandro Belotti, Katia Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna Esposito, Michele Nichelatti, Manel Esteller, Salvatore Siena

Dataset

Supplementary Table 1 from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Alessio Amatu, Andrea Sartore‐Bianchi, Cátia Moutinho, Alessandro Belotti, Katia Bencardino, Giuseppe Chirico, Andrea Cassingena, Francesca Rusconi, Anna Esposito, Michele Nichelatti, Manel Esteller, Salvatore Siena

Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

Discussion(0)

Related publications

Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.

Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Data from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Data from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer

Supplementary Table 1 from Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer